Lilly (LLY) and Incyte (INCY) communicate review extension of sNDA for baricitinib for treatment of moderate to severe atopic dermatitis
Go back to Lilly (LLY) and Incyte (INCY) communicate review extension of sNDA for baricitinib for treatment of moderate to severe atopic dermatitis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 52.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.72 | 52 Week High | $118.49 | |||
| Open | $52.72 | 52 Week Low | $55.00 | |||
| Day High | $52.72 | P/E | N/A | |||
| Day Low | $52.72 | EPS | $-0.56 | |||
| Volume | 5 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 750.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $750.77 | 52 Week High | $88.16 | |||
| Open | $750.77 | 52 Week Low | $67.88 | |||
| Day High | $750.77 | P/E | 173.79 | |||
| Day Low | $750.77 | EPS | $4.32 | |||
| Volume | 2,153 | |||||
